27703744|t|Adjunctive aripiprazole in risperidone - induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial
27703744|a|Hyperprolactinaemia is a troublesome side-effect of treatment with antipsychotics. This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone. Thirty patients taking risperidone were enrolled into the trial (CTRI/2012/11/003114). Aripiprazole was administered at a fixed daily dose of 10 mg/day for 8 weeks. Serum prolactin was measured at baseline and at 8 weeks. Hyperprolactinaemia -related problems, psychopathology and side-effects were evaluated every 2 weeks. Prolactin levels decreased by 58% in the aripiprazole group compared with an increase by 22% in the placebo group. Prolactin levels normalised in 46% of patients in the aripiprazole group (number needed to treat, NNT=2). Aripiprazole improved erectile dysfunction in five out of six patients. There were no significant differences in change in psychopathology or side-effects between groups. Adjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. This is a potential treatment for hyperprolactinaemia observed during treatment with second-generation antipsychotics. None. Â© The Royal College of Psychiatrists 2015. This is an open access article distributed under the terms of the Creative Commons Non-Commercial, No Derivatives (CC BY-NC-ND) licence.
27703744	0	10	Adjunctive	T061	C3858690
27703744	11	23	aripiprazole	T109,T121	C0299792
27703744	27	38	risperidone	T109,T121	C0073393
27703744	41	48	induced	T169	C0205263
27703744	49	68	hyperprolactinaemia	T047	C0020514
27703744	70	82	double-blind	T062	C0013072
27703744	84	94	randomised	T062,T170	C0282440
27703744	96	120	placebo-controlled trial	T062	C1706408
27703744	121	140	Hyperprolactinaemia	T047	C0020514
27703744	158	169	side-effect	T046	C0879626
27703744	173	182	treatment	T061	C0087111
27703744	188	202	antipsychotics	T121	C0040615
27703744	209	221	double-blind	T062	C0013072
27703744	223	247	placebo-controlled study	T062	C1706408
27703744	271	277	effect	T080	C1280500
27703744	281	301	adjunctive treatment	T061	C3858690
27703744	307	325	10 mg aripiprazole	T200	C1166429
27703744	329	345	prolactin levels	T059	C0373706
27703744	350	356	sexual	T053	C0036864
27703744	357	369	side-effects	T046	C0879626
27703744	373	381	patients	T101	C0030705
27703744	387	400	schizophrenia	T048	C0036341
27703744	401	416	symptomatically	T169	C0231220
27703744	417	427	maintained	T169	C1314677
27703744	431	442	risperidone	T109,T121	C0073393
27703744	451	459	patients	T101	C0030705
27703744	467	478	risperidone	T109,T121	C0073393
27703744	502	507	trial	T062	C0008976
27703744	531	543	Aripiprazole	T109,T121	C0299792
27703744	548	560	administered	T058	C0806914
27703744	572	582	daily dose	T081	C2348070
27703744	609	624	Serum prolactin	T059	C1277972
27703744	641	649	baseline	T081	C1442488
27703744	666	685	Hyperprolactinaemia	T047	C0020514
27703744	695	703	problems	T033	C0033213
27703744	705	720	psychopathology	T048	C0004936
27703744	725	737	side-effects	T046	C0879626
27703744	743	752	evaluated	T058	C0220825
27703744	768	794	Prolactin levels decreased	T033	C0857016
27703744	809	821	aripiprazole	T109,T121	C0299792
27703744	822	827	group	T078	C0441833
27703744	845	853	increase	T169	C0442805
27703744	868	881	placebo group	T078	C0441833
27703744	883	910	Prolactin levels normalised	T033	C0580441
27703744	921	929	patients	T101	C0030705
27703744	937	949	aripiprazole	T109,T121	C0299792
27703744	950	955	group	T078	C0441833
27703744	989	1001	Aripiprazole	T109,T121	C0299792
27703744	1002	1010	improved	T033	C0184511
27703744	1011	1031	erectile dysfunction	T047	C0242350
27703744	1051	1059	patients	T101	C0030705
27703744	1075	1086	significant	T078	C0750502
27703744	1087	1098	differences	T080	C1705242
27703744	1102	1108	change	T081	C0443172
27703744	1112	1127	psychopathology	T048	C0004936
27703744	1131	1143	side-effects	T046	C0879626
27703744	1152	1158	groups	T078	C0441833
27703744	1160	1170	Adjunctive	T061	C3858690
27703744	1171	1183	aripiprazole	T109,T121	C0299792
27703744	1184	1191	reduced	T080	C0392756
27703744	1192	1208	prolactin levels	T059	C0373706
27703744	1218	1230	treated with	T061	C0332293
27703744	1231	1242	risperidone	T109,T121	C0073393
27703744	1249	1258	no effect	T080	C1301751
27703744	1262	1277	psychopathology	T048	C0004936
27703744	1282	1305	extrapyramidal symptoms	T184	C0234133
27703744	1317	1326	potential	T080	C3245505
27703744	1327	1336	treatment	T061	C0087111
27703744	1341	1360	hyperprolactinaemia	T047	C0020514
27703744	1361	1369	observed	T169	C1441672
27703744	1370	1376	during	T079	C0347984
27703744	1377	1386	treatment	T061	C0087111
27703744	1392	1424	second-generation antipsychotics	T121	C0040615